Elekta (OTCMKTS:EKTAY) Sees Unusually-High Trading Volume – Should You Buy?

by · The Markets Daily

Shares of Elekta AB (OTCMKTS:EKTAY – Get Free Report) saw strong trading volume on Tuesday . Approximately 6,183 shares traded hands during mid-day trading, an increase of 106% from the previous session’s volume of 3,007 shares.The stock last traded at $5.1249 and had previously closed at $5.0490.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised shares of Elekta from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Reduce”.

View Our Latest Analysis on EKTAY

Elekta Trading Up 0.6%

The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.68 and a current ratio of 0.87. The firm has a market capitalization of $1.89 billion, a P/E ratio of -32.00 and a beta of 1.01. The firm has a 50 day moving average price of $5.24 and a two-hundred day moving average price of $5.83.

Elekta (OTCMKTS:EKTAY – Get Free Report) last announced its earnings results on Thursday, May 28th. The company reported $0.06 earnings per share (EPS) for the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%.The company had revenue of $521.00 million for the quarter. On average, equities research analysts expect that Elekta AB will post 0.43 EPS for the current fiscal year.

About Elekta

(Get Free Report)

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.

Recommended Stories